Prescription medicine
Indium in 111 oxyquinoline
Indium in 111 oxyquinoline is a prescription medicine with an FDA approval on record since 1985. FDA's NDC Directory lists it from 1 generic labeler.
- Generic listed
Check it at the source: the indium in 111 oxyquinoline FDA label on DailyMed (effective January 10, 2024, Medi-Physics Inc. dba GE Healthcare.); the NDA 19044 record on Drugs@FDA; every indium in 111 oxyquinoline label on DailyMed.
Highlights of the record
FDA label of January 10, 2024; NDC Directory, Drugs@FDA and Orange Book, October 8, 2026
Used for
From the label: indications and usageIndium In 111 Oxyquinoline Solution is indicated for radiolabeling autologous leukocytes.
Forms and strengths
Liquid; solution.
On the market
- Earliest approval on file
- December 24, 1985 Indium In 111 Oxyquinoline, Ge Healthcare; Drugs@FDA’s file, where older or withdrawn approvals can be missing
- Generic approvals
- 1 first July 25, 2018; 1 with a marketed status in Drugs@FDA
- Labelers listed (NDC)
- 2 of which 1 under generic applications, 1 under brand applications, repackagers included
Supply and safety
- Pharmacy cost (NADAC)
- Not in the survey
- Shortage (FDA)
- No current entry
- Recalls by its makers (FDA)
- No recall recorded
- FAERS reports
- 5 through July 30, 2026
What is indium in 111 oxyquinoline used for?
From the label: indications and usageIndium In 111 Oxyquinoline Solution is indicated for radiolabeling autologous leukocytes. Indium In 111 oxyquinoline labeled leukocytes may be used as an adjunct in the detection of inflammatory processes to which leukocytes migrate, such as those associated with abscesses or other infection, following reinjection and detection by appropriate imaging procedures. The degree of accuracy may vary with labeling techniques and with the size, location and nature of the inflammatory process. Indium In 111 oxyquinoline labeled leukocyte imaging is not the preferred technique for the initial evaluation of patients with a high clinical probability of an abscess in a known location. […]
FDA pharmacologic class: Radioactive Diagnostic Agent.
Source: FDA drug label (Indium in 111 Oxyquinoline), Medi-Physics Inc. dba GE Healthcare., effective January 10, 2024 (SPL set 4c52c904-8137-4b10-8a85-d9b96c2d8a00), via openFDA; the full label on DailyMed
Is there a generic for indium in 111 oxyquinoline?
The FDA approved the first generic indium in 111 oxyquinoline on July 25, 2018. 1 generic application is approved; 1 of it carries a current (not discontinued) marketing status in Drugs@FDA; that status is not evidence that the generic is on sale.
FDA's NDC Directory lists indium in 111 oxyquinoline from 1 labeler under a generic (ANDA) application and from 1 brand labeler. A listing means the company has registered the product for sale; it does not show that every pharmacy stocks it.
- 1985 earliest approval on file
- 2018 first generic approved
Source: Drugs@FDA, FDA NDC Directory and the Orange Book (openFDA bulk files, October 8, 2026)
What do FAERS reports show for indium in 111 oxyquinoline?
The FDA Adverse Event Reporting System holds 5 reports that list indium in 111 oxyquinoline among the medicines taken, through July 30, 2026, each a report of something that happened, not proof the medicine caused it; 1 are coded as a death and 1 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is.
The most reported reactions
Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026
What next?
- Other radioactive diagnostic agents
- the pharmacologic class, with prices and generics
- Indium in 111 oxyquinoline side effects
- the label's list beside FAERS reports
- Check an interaction
- what two or more labels say about each other